Skip to content

CapEx at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$11K
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$1.64M+518%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$18K+800%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$434K-7.1%
Alumis Inc. logo
Alumis Inc.ALMS
$164K+343%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$230.6M+0.6%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+259%
Enterprise value$700.21M+179%
P/S159.6×+87.1×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's capex?
DBV Technologies (DBVT) reported capex of $400K in Q1 2026.
What is the long-term trend for DBV Technologies's capex?
Over 3 years (2022 to 2025), DBV Technologies's capex has grown at a -11.0% compound annual growth rate (CAGR), from $754K to $532K.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.